Asimov

Asimov is developing a synthetic biology platform – from cells to software – to design and manufacture next-generation therapeutics, including biologics, cell/gene therapies, and RNA through a combination of products, services, and collaborations.

At Advanced Therapies Congress, we’ll be presenting our LV Edge System for lentivirus production, which integrates stable cell lines and software design tools to routinely achieve lentiviral titers over 1E8 TU/mL for therapeutic transgenes.

Founded by bioengineers from MIT and Boston University and headquartered in Boston, the company has raised over $200 million from top institutional investors including Andreessen Horowitz, CPP Investments, Horizons Ventures, and Fidelity Management & Research Company. For more information, visit www.asimov.com